

INTRODUCTION - PET BRIEFING PACKAGE

These materials are FDA's initial draft reviews of the published literature regarding the use of F-18 Fluorodeoxyglucose for oncology and cardiac indications; the use of N-13 Ammonia for myocardial perfusion; and the use of O-15 Water for brain perfusion. Because these reviews are based entirely on publicly available literature and the conclusions in the reviews have been previously discussed in public meetings and elsewhere, FDA is providing the reviews in their entirety for public reading and copying.

These review documents are initial, draft documents that do not represent final agency scientific or regulatory determinations on the products discussed. These preliminary agency findings may be modified further based on input from advisory committee discussions and recommendations and further agency review.